Literature DB >> 28189703

Characterization of butyrylcholinesterase in bovine serum.

Alicia J Dafferner1, Sofya Lushchekina2, Patrick Masson3, Gaoping Xiao4, Lawrence M Schopfer5, Oksana Lockridge6.   

Abstract

Human butyrylcholinesterase (HuBChE) protects from nerve agent toxicity. Our goal was to determine whether bovine serum could be used as a source of BChE. Bovine BChE (BoBChE) was immunopurified from 100 mL fetal bovine serum (FBS) or 380 mL adult bovine serum by binding to immobilized monoclonal mAb2. Bound proteins were digested with trypsin and analyzed by liquid chromatography-tandem mass spectrometry. The results proved that FBS and adult bovine serum contain BoBChE. The concentration of BoBChE was estimated to be 0.04 μg/mL in FBS, and 0.03 μg/mL in adult bovine serum, values lower than the 4 μg/mL BChE in human serum. Nondenaturing gel electrophoresis showed that monoclonal mAb2 bound BoBChE but not bovine acetylcholinesterase (BoAChE) and confirmed that FBS contains BoBChE and BoAChE. Recombinant bovine BChE (rBoBChE) expressed in serum-free culture medium spontaneously reactivated from inhibition by chlorpyrifos oxon at a rate of 0.0023 min-1 (t1/2 = 301 min-1) and aged at a rate of 0.0138 min-1 (t1/2 = 50 min-1). Both BoBChE and HuBChE have 574 amino acids per subunit and 90% sequence identity. However, the apparent size of serum BoBChE and rBoBChE tetramers was much greater than the 340,000 Da of HuBChE tetramers. Whereas HuBChE tetramers include short polyproline rich peptides derived from lamellipodin, no polyproline peptides have been identified in BoBChE. We hypothesize that BoBChE tetramers use a large polyproline-rich protein to organize subunits into a tetramer and that the low concentration of BoBChE in serum is explained by limited quantities of an unidentified polyproline-rich protein.
Copyright © 2017 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Bovine butyrylcholinesterase; Immunopurification; Mass spectrometry; Molecular dynamics; Serum

Mesh:

Substances:

Year:  2017        PMID: 28189703      PMCID: PMC5383351          DOI: 10.1016/j.cbi.2017.02.004

Source DB:  PubMed          Journal:  Chem Biol Interact        ISSN: 0009-2797            Impact factor:   5.192


  56 in total

1.  Retrospective detection of exposure to organophosphorus anti-cholinesterases: mass spectrometric analysis of phosphylated human butyrylcholinesterase.

Authors:  A Fidder; A G Hulst; D Noort; R de Ruiter; M J van der Schans; H P Benschop; J P Langenberg
Journal:  Chem Res Toxicol       Date:  2002-04       Impact factor: 3.739

2.  A "DIRECT-COLORING" THIOCHOLINE METHOD FOR CHOLINESTERASES.

Authors:  M J KARNOVSKY; L ROOTS
Journal:  J Histochem Cytochem       Date:  1964-03       Impact factor: 2.479

3.  Monoclonal antibodies to human butyrylcholinesterase reactive with butyrylcholinesterase in animal plasma.

Authors:  Hong Peng; Stephen Brimijoin; Anna Hrabovska; Eric Krejci; Thomas A Blake; Rudolph C Johnson; Patrick Masson; Oksana Lockridge
Journal:  Chem Biol Interact       Date:  2015-11-14       Impact factor: 5.192

4.  X-ray crystallographic snapshots of reaction intermediates in the G117H mutant of human butyrylcholinesterase, a nerve agent target engineered into a catalytic bioscavenger.

Authors:  Florian Nachon; Eugenie Carletti; Marielle Wandhammer; Yvain Nicolet; Lawrence M Schopfer; Patrick Masson; Oksana Lockridge
Journal:  Biochem J       Date:  2011-02-15       Impact factor: 3.857

5.  Direct quantitation of methyl phosphonate adducts to human serum butyrylcholinesterase by immunomagnetic-UHPLC-MS/MS.

Authors:  Melissa D Carter; Brian S Crow; Brooke G Pantazides; Caroline M Watson; Jerry D Thomas; Thomas A Blake; Rudolph C Johnson
Journal:  Anal Chem       Date:  2013-11-08       Impact factor: 6.986

6.  Pharmacokinetics and immunologic consequences of exposing macaques to purified homologous butyrylcholinesterase.

Authors:  Yvonne Rosenberg; Chunyuan Luo; Yacov Ashani; Bhupendra P Doctor; Randy Fischer; Gary Wolfe; Ashima Saxena
Journal:  Life Sci       Date:  2002-11-29       Impact factor: 5.037

7.  Automation of the CHARMM General Force Field (CGenFF) II: assignment of bonded parameters and partial atomic charges.

Authors:  K Vanommeslaeghe; E Prabhu Raman; A D MacKerell
Journal:  J Chem Inf Model       Date:  2012-11-28       Impact factor: 4.956

8.  Optimization of the additive CHARMM all-atom protein force field targeting improved sampling of the backbone φ, ψ and side-chain χ(1) and χ(2) dihedral angles.

Authors:  Robert B Best; Xiao Zhu; Jihyun Shim; Pedro E M Lopes; Jeetain Mittal; Michael Feig; Alexander D Mackerell
Journal:  J Chem Theory Comput       Date:  2012-07-18       Impact factor: 6.006

9.  Production and characterization of separate monoclonal antibodies to human acetylcholinesterase and butyrylcholinesterase.

Authors:  S Brimijoin; K P Mintz; M C Alley
Journal:  Mol Pharmacol       Date:  1983-11       Impact factor: 4.436

10.  Comparison of 5 monoclonal antibodies for immunopurification of human butyrylcholinesterase on Dynabeads: KD values, binding pairs, and amino acid sequences.

Authors:  Hong Peng; Stephen Brimijoin; Anna Hrabovska; Katarina Targosova; Eric Krejci; Thomas A Blake; Rudolph C Johnson; Patrick Masson; Oksana Lockridge
Journal:  Chem Biol Interact       Date:  2015-09-03       Impact factor: 5.192

View more
  5 in total

1.  Polyproline-rich peptides associated with Torpedo californica acetylcholinesterase tetramers.

Authors:  Lilly Toker; Israel Silman; Tzviya Zeev-Ben-Mordehai; Joel L Sussman; Lawrence M Schopfer; Oksana Lockridge
Journal:  Chem Biol Interact       Date:  2020-02-20       Impact factor: 5.192

2.  Purification of recombinant human butyrylcholinesterase on Hupresin®.

Authors:  Oksana Lockridge; Emilie David; Lawrence M Schopfer; Patrick Masson; Xavier Brazzolotto; Florian Nachon
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2018-10-25       Impact factor: 3.205

3.  Pharmacokinetics and Dialytic Clearance of Isavuconazole During In Vitro and In Vivo Continuous Renal Replacement Therapy.

Authors:  M Biagi; D Butler; X Tan; S Qasmieh; K Tejani; S Patel; R M Rivosecchi; M H Nguyen; C J Clancy; R K Shields; E Wenzler
Journal:  Antimicrob Agents Chemother       Date:  2019-09-16       Impact factor: 5.191

4.  Polymer-free corticosteroid dimer implants for controlled and sustained drug delivery.

Authors:  Kyle Battiston; Ian Parrag; Matthew Statham; Dimitra Louka; Hans Fischer; Gillian Mackey; Adam Daley; Fan Gu; Emily Baldwin; Bingqing Yang; Ben Muirhead; Emily Anne Hicks; Heather Sheardown; Leonid Kalachev; Christopher Crean; Jeffrey Edelman; J Paul Santerre; Wendy Naimark
Journal:  Nat Commun       Date:  2021-05-17       Impact factor: 14.919

5.  Optimization of Cholinesterase-Based Catalytic Bioscavengers Against Organophosphorus Agents.

Authors:  Sofya V Lushchekina; Lawrence M Schopfer; Bella L Grigorenko; Alexander V Nemukhin; Sergei D Varfolomeev; Oksana Lockridge; Patrick Masson
Journal:  Front Pharmacol       Date:  2018-03-13       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.